Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.
Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.
复制标题
DOI：
10.1158/2159-8290.cd-13-0197
复制
发表时间：
2014-02
期刊：
影响因子：
28.2
通讯作者：
Rosenstein BS
中科院分区：
文献类型：
--
作者：
Kerns SL;Ostrer H;Rosenstein BS
放疗后正常组织的不良反应很常见，严重影响患者的生活质量。这些影响不能仅由剂量学、治疗或人口统计因素来解释，而且有证据表明，常见的基因变异与放射治疗的不良反应有关。放射基因组学领域已经发展到识别这样的遗传风险因素。放射基因组学有两个目标：1)开发一种分析方法，以预测哪些癌症患者最有可能因放射治疗而发生辐射损伤；2)获得有关辐射诱导的正常组织毒性的分子途径的信息。本文对该领域的发展历史和研究现状进行了综述。
Normal tissue adverse effects following radiotherapy are common and significantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: 1) develop an assay to predict which cancer patients are most likely to develop radiation injuries resulting from radiotherapy, and 2) obtain information about the molecular pathways responsible for radiation-induced normal tissue toxicities. This review summarizes the history of the field and current research.